ACRV Stock Forecast: Acrivon Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.15
−17.86% on the day

The median 12-month analyst price target for Acrivon Therapeutics, Inc. is $11. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 65 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$49.3M
Ticker Nerd rank
65/ 100
Median analyst target
$11
Analysts covering
7
Revenue$0.0
Operating income−$18.7M
Net income−$18.0M
Free cash flow−$14.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−20.7%
1M
−35.9%
YTD
−52.3%
1Y
−49.1%
From 52W high
−61.8%
From 52W low
0.0%
$1.15
$3.01
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Acrivon Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
65/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
79
Revisions
72
Growth
66
Momentum
53
Issuance
44
Volatility
43
Quality
38
Value
28

Accruals (79): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (28): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ACRV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACRV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26ACRVHigh $19Median $11Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7
Buy
0
Hold
0
Sell
$7
Low
$11
Median
$19
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Nov 2026CitizensReiteratesMarket Outperform$13
9 Jan 2026Piper SandlerMaintainsOverweight$6.00 → $8.00
25 Nov 2025HC Wainwright & Co.ReiteratesBuy—
14 Aug 2025OppenheimerMaintainsOutperform—
16 May 2025Jones TradingDowngradeHold—
15 May 2025OppenheimerMaintainsOutperform—
28 Mar 2025HC Wainwright & Co.ReiteratesBuy—
28 Mar 2025OppenheimerMaintainsOutperform—
26 Mar 2025Cantor FitzgeraldReiteratesOverweight—
26 Mar 2025Citizens Capital MarketsReiteratesMarket Outperform—
26 Mar 2025HC Wainwright & Co.MaintainsBuy—
31 Jan 2025Cantor FitzgeraldInitiatesOverweight—
14 Nov 2024BMO CapitalMaintainsOutperform—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024HC Wainwright& Co.ReiteratesBuy—
16 Sept 2024BMO CapitalReiteratesOutperform—
16 Sept 2024HC Wainwright & Co.ReiteratesBuy—
16 Sept 2024JMP SecuritiesReiteratesMarket Outperform—
16 Sept 2024Ladenburg ThalmannUpgradeBuy—
13 Aug 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ACRV.

Market Radar

This page is one stock. Monday covers all of them.

ACRV appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ACRV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Acrivon Therapeutics, Inc. returned −49.1% against +6.9% for the S&P 500, dividends included.

ACRV vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26ACRVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ACRV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.7×

Cheaper than 80% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−74.1%

Higher than 17% of US stocks

Return on assets
−41.8%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Acrivon Therapeutics, Inc. has a market value of $49.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$74.2M.

  • Free cash flow in the twelve months to 30 June 2026: −$64.1M.

  • Shares outstanding: 42.8M.

  • Acrivon Therapeutics, Inc. employs 74 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

ACRV and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ACRVAcrivon Therapeutics, Inc.$49.3M65
IMAImageneBio, Inc.$48.8M33
HRTXHeron Therapeutics, Inc.$47.9M54
ALDXAldeyra Therapeutics, Inc.$50.7M60
CNXUConexeu Sciences, Inc.$47.8M1
ONCYOncolytics Biotech, Inc.$47.7M38
VRCAVerrica Pharmaceuticals, Inc.$47.1M49

Take a look at ACRV’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Acrivon Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ACRV

What is the ACRV stock price forecast for 2026-2027?

The median 12-month analyst price target for Acrivon Therapeutics, Inc. is $11, with estimates ranging from $7 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACRV stock a buy right now?

Of the 7 analysts covering Acrivon Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Acrivon Therapeutics, Inc. 65 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACRV?

As at 21 Nov 2026, Acrivon Therapeutics, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (79 of 100).

Will ACRV stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts is $11, and Ticker Nerd's factor model ranks Acrivon Therapeutics, Inc. 65 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACRV stock forecast for 2030?

No analyst covering Acrivon Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACRV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $19 over the next 12 months.

How has ACRV stock performed over the past year?

Acrivon Therapeutics, Inc. returned -49.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Acrivon Therapeutics, Inc. do?

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology. The company develops cancer medicines using its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, which is designed to match drug mechanisms with the biological drivers of each tumor and identify patients most likely to respond.

Company

About Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology. The company develops cancer medicines using its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, which is designed to match drug mechanisms with the biological drivers of each tumor and identify patients most likely to respond. Its current work centers on targeted therapies and companion diagnostics for solid tumors, with programs spanning DNA damage response and cell-cycle regulation pathways. Acrivon Therapeutics also develops its OncoSignature diagnostic approach to support patient selection in clinical development. Headquartered in Watertown, Massachusetts, Acrivon Therapeutics plays a specialized role in the biopharmaceutical market by combining drug discovery, biomarker development, and clinical research to advance more selective oncology treatments.

CEO Dr. Peter Blume-Jensen M.D., Ph.D. · 74 employees · United States · https://acrivon.com